Carewell Steuart Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 19-12-2024
- Paid Up Capital ₹ 0.80 M
as on 19-12-2024
- Company Age 16 Year, 24 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.35 Cr
as on 19-12-2024
- Revenue 33.21%
(FY 2020)
- Profit 133.85%
(FY 2020)
- Ebitda 174.25%
(FY 2020)
- Net Worth 71.12%
(FY 2020)
- Total Assets -3.27%
(FY 2020)
About Carewell Steuart Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M.
The company currently has active open charges totaling ₹10.35 Cr.
Chandrasekaran Venkatarayalu and Narasimhan Dhandapani serve as directors at the Company.
- CIN/LLPIN
U74990TN2008PTC070035
- Company No.
070035
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Dec 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Carewell Steuart Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandrasekaran Venkatarayalu  | Managing Director | 01-Dec-2008 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Narasimhan Dhandapani | Director | 01-Dec-2008 | Current |
Financial Performance of Carewell Steuart Pharma.
Carewell Steuart Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 33.21% increase. The company also saw a substantial improvement in profitability, with a 133.85% increase in profit. The company's net worth Soared by an impressive increase of 71.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Carewell Steuart Pharma?
In 2019, Carewell Steuart Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jaydan Impex Private LimitedActive 28 years 6 monthsChandrasekaran Venkatarayalu is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 09 Mar 2023 | ₹4.85 Cr | Open |
Indian Bank Creation Date: 06 Sep 2022 | ₹2.30 Cr | Open |
Indian Bank Creation Date: 15 Dec 2011 | ₹2.00 M | Open |
How Many Employees Work at Carewell Steuart Pharma?
Carewell Steuart Pharma has a workforce of 29 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Carewell Steuart Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Carewell Steuart Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
